U.S. Food and Drug Administration Approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

On January 22, 2021

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

Boeing’s Starliner Spacecraft Completes Successful Docking to Space Station

Entergy’s Palisades team finishes strong as facility shuts down